Lung Cancer
Volume 45 , Pages S133-S135 , August 2004

Malignant mesothelioma—the UK experience

References 

  1. Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality in Britain. Lancet. 1995;345:535–539
  2. Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA, O’Byrne KJ. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax. 2000;55:731–735
  3. Middleton GW, Smith IE, O’Brien ME, Norton A, Hickish T, Priest K, et al.  Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann. Oncol. 1998;9:269–273
  4. Steele JPC, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2000;18:3912–3917
  5. Grange JM, Stanford JL, Rook GAW. Tuberculosis and cancer: parallels in host responses and therapeutic approaches?. Lancet. 1995;345:1350–1352
  6. O’Brien ME, Saini A, Smith IE, Webb A, Gregory K, Mendes R, et al.  A pilot randomised study of SRL172 combined with chemotherapy in patients with advanced inoperable non-small cell lung cancer and mesothelioma. Br. J. Cancer. 2000;83:853–857
  7. Assersohn L, Souberbielle BE, O’Brien ME, Archer CD, Mendes R, Bass R, et al.  A randomised pilot study of SRL172 (Mycobacterium vaccae) in patients with small cell lung cancer (SCLC) treated with chemotherapy. Br. J. Cancer. 2000;83(Suppl 1):43
  8. Mendes R, O’Brien ME, Mitra A, Norton A, Gregory RK, Padhani AR, et al.  Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma. Br. J. Cancer. 2002;86(3):336–341

PII: S0169-5002(04)00185-0

doi: 10.1016/j.lungcan.2004.04.024

Lung Cancer
Volume 45 , Pages S133-S135 , August 2004

Article Tools